Technical Analysis for XRTX - Xortx Therapeutics Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | -0.53% | |
| Gapped Up | Strength | -0.53% | |
| Spinning Top | Other | 8.05% | |
| Below Lower BB | Weakness | 8.05% | |
| Gapped Down | Weakness | 8.05% | |
| Lower Bollinger Band Touch | Weakness | 8.05% | |
| Hammer Candlestick | Bullish | -3.59% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Rose Above Previous Day's High | 2 days ago |
| Gap Up Partially Closed | 2 days ago |
| Gapped Up (Partial) | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 2024-11-12
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Organ Systems Diabetes Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.35 |
| 52 Week Low | 0.37 |
| Average Volume | 6,088 |
| 200-Day Moving Average | 3.192 |
| 50-Day Moving Average | 2.204 |
| 20-Day Moving Average | 2.017 |
| 10-Day Moving Average | 1.964 |
| Average True Range | 0.190 |
| RSI (14) | 42.86 |
| ADX | 15.34 |
| +DI | 20.729 |
| -DI | 27.898 |
| Chandelier Exit (Long, 3 ATRs) | 2.119 |
| Chandelier Exit (Short, 3 ATRs) | 2.251 |
| Upper Bollinger Bands | 2.265 |
| Lower Bollinger Band | 1.768 |
| Percent B (%b) | 0.22 |
| BandWidth | 24.607 |
| MACD Line | -0.103 |
| MACD Signal Line | -0.090 |
| MACD Histogram | -0.0131 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.910 | ||||
| Resistance 3 (R3) | 1.913 | 1.907 | 1.905 | ||
| Resistance 2 (R2) | 1.907 | 1.899 | 1.905 | 1.903 | |
| Resistance 1 (R1) | 1.893 | 1.894 | 1.890 | 1.890 | 1.902 |
| Pivot Point | 1.887 | 1.887 | 1.885 | 1.885 | 1.887 |
| Support 1 (S1) | 1.873 | 1.879 | 1.870 | 1.870 | 1.858 |
| Support 2 (S2) | 1.867 | 1.874 | 1.865 | 1.857 | |
| Support 3 (S3) | 1.853 | 1.867 | 1.855 | ||
| Support 4 (S4) | 1.850 |
